AC Immune SA
Nasdaq ACIU · 1015 Lausanne, Switzerland
Works in Genetic & rare · Metabolic & endocrine · Neurology · Psychiatry
AC Immune SA is a clinical trial sponsor based in 1015 Lausanne, Switzerland, listed as Nasdaq ACIU. It has 5 active clinical trials with 659 planned participants, in Genetic & rare, Metabolic & endocrine, Neurology and Psychiatry. Since 2021 it has completed 2 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq ACIU
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about AC Immune SA
AC Immune SA is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 659 planned participants, in Genetic & rare, Metabolic & endocrine, Neurology, Psychiatry. Since 2021 it has completed 2 trials and stopped 1 early.
AC Immune SA is based in 1015 Lausanne, Switzerland and is listed as Nasdaq ACIU. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with AC Immune SA; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-01.
Approve Suite is not affiliated with AC Immune SA.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.